# Differential Effects of in Vivo and Virtual Exposure Therapy in Agoraphobia > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/endocannabinoid-system-anxiety-treatment-research-agoraphobia-trial/ > **Published:** 2026-05-08T15:06:53-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T17:15:41-04:00 > **Clinical Summary:** New clinical trial examines how endocannabinoid system anxiety treatment research could transform agoraphobia therapy through VR exposure and biomarker analysis --- CED Clinical Relevance  #76Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. 🧪 [Clinical Trial](https://cedclinic.com/marijuana-reclassification-impact-cannabis-companies/) Watch  |  CED Clinic Trial ID NCT06514495 Status Recruiting Condition Agoraphobia; Panic Intervention Therapy Why This Matters Agoraphobia affects millions yet many patients avoid exposure therapy, the gold standard treatment, due to its intensity. This trial investigates whether virtual reality exposure therapy could provide comparable benefits to traditional in-vivo exposure while examining biological mechanisms that could predict treatment success. Clinical Summary This is a [clinical trial](https://cedclinic.com/marijuana-reclassification-impact-cannabis-companies/) comparing in-vivo exposure therapy to Virtual Reality Exposure Therapy (VRET) for agoraphobia patients. The study examines treatment outcomes alongside interoceptive accuracy (body awareness) and [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) function as potential biomarkers. Researchers are investigating how these biological systems influence therapy response and whether VR exposure can match the efficacy of traditional exposure methods. The trial is currently recruiting participants with agoraphobia and panic disorder. Dr. Caplan’s Take “If this trial demonstrates that VR exposure therapy produces comparable outcomes to traditional exposure, it could dramatically expand access to effective treatment for agoraphobia patients who find in-person exposure too daunting. Understanding endocannabinoid involvement could also inform future cannabis-based adjunct therapies.” Clinical Perspective 🧠 Patients considering this trial should know they may receive either traditional or VR-based exposure therapy, both evidence-based approaches. Clinicians should note this research could validate VR as a legitimate alternative to in-vivo exposure, potentially improving treatment engagement and accessibility for [anxiety disorders](https://cedclinic.com/adolescent-cannabis-use-and-anxiety-research/). 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Differential%20Effects%20of%20in%20Vivo%20and%20Virtual%20Exposure%20Therapy%20in%20Agoraphobia%20%40drcaplan&url=https%3A//clinicaltrials.gov/study/NCT06514495)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//clinicaltrials.gov/study/NCT06514495)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Differential%20Effects%20of%20in%20Vivo%20and%20Virtual%20Exposure%20Therapy%20in%20Agoraphobia%20--%20via%20%40drcaplan.bsky.social%20https%3A//clinicaltrials.gov/study/NCT06514495)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://clinicaltrials.gov/study/NCT06514495](https://clinicaltrials.gov/study/NCT06514495) Table of Contents - [FAQ](#FAQ)[What is this agoraphobia trial comparing?](#What_is_this_agoraphobia_trial_comparing) - [Does this agoraphobia trial involve cannabis or cannabinoid treatment?](#Does_this_agoraphobia_trial_involve_cannabis_or_cannabinoid_treatment) - [Who can take part in this exposure therapy trial?](#Who_can_take_part_in_this_exposure_therapy_trial) - [Related](#Related) ## FAQ ### What is this agoraphobia trial comparing? The trial compares traditional in-vivo exposure therapy with Virtual Reality Exposure Therapy (VRET) for people with agoraphobia. Researchers are examining treatment outcomes and whether VR exposure can match the efficacy of traditional exposure methods. The trial is registered as NCT06514495. ### Does this agoraphobia trial involve cannabis or cannabinoid treatment? The listing does not describe any cannabis treatment; the intervention is therapy. Instead, the trial measures [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) function, along with interoceptive accuracy, or body awareness, as potential biomarkers. Researchers are investigating how these biological systems influence response to exposure therapy. ### Who can take part in this exposure therapy trial? The trial is currently recruiting people with agoraphobia and panic disorder. Those who take part may receive either traditional in-vivo exposure therapy or virtual reality exposure therapy, both of which the article describes as evidence-based approaches. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).